Latest Headlines

  1. Nanoform Starts Pivotal Human Bioequivalence Studies Of Nanoenzalutamide 6/12/2025

    Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started pivotal relative bioequivalence studies of Nanoenzalutamide, the nanocrystalline-enabled enzalutamide tablet formulation, a potential alternative to the amorphous solid dispersion (ASD) used in XTANDI® (enzalutamide) [1], the number one prescribed androgen receptor inhibitor [2] approved to treat prostate cancer.

  2. CDMO Bora Pharmaceuticals Procures New Aseptic Filling And Closing System From AST 5/29/2025

    AST, a leading provider of flexible drug product manufacturing solutions, has announced the placement of its advanced isolated GENiSYS C fill-finish system with Bora Pharmaceuticals, a premier international contract development and manufacturing organization (CDMO). The flexible, multi-format system will be placed in their 87,000-square-foot clinical-to-commercial drug product manufacturing facility in Baltimore, Maryland.

  3. Australia Delivers Certainty For US Biotechs In 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, And R&D Rebates 5/28/2025

    As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials. With its globally accepted regulatory framework, accelerated timelines, and 43.5% R&D rebate, Australia offers a compelling advantage — and Avance Clinical, Australia’s leading early-phase specialist CRO, is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate their programs.

  4. Cellular Origins And 3P innovation Collaborate To Accelerate Industrialisation Of CGT Manufacturing 5/21/2025

    Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a collaboration with 3P innovation, a leading engineering company and supplier of automated fill-finish equipment.

  5. Meet With Avance Clinical At ASCO 2025 In Chicago 5/20/2025

    Avance Clinical will attend and host a booth at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. This premier event brings together oncology professionals from around the world to connect, collaborate, and inspire advancements in cancer care.

  6. Avance Clinical Honored With Frost & Sullivan's 2025 Global Customer Value Leadership Award 5/20/2025

    Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company’s outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization.

  7. VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ At 2025 ASGCT Annual Meeting 5/15/2025

    VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.  

  8. Novotech Welcomes New Investment From GIC, Temasek, And Existing Investor TPG To Accelerate Global Growth 5/14/2025

    Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.

  9. Novotech Report Reveals Global Surge In Infectious Disease Trials As Industry Nears 2,000 Studies Since 2020 5/14/2025

    Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released a new report analyzing the evolving infectious disease clinical trial landscape. This report provides critical strategic insights for pharmaceutical and biotech companies navigating the complexities of global infectious disease research and development in 2025. 

  10. Novotech Identifies Strategic Opportunities In Idiopathic Pulmonary Fibrosis Trials With Release Of Global Market Insights 5/14/2025

    Sydney, April 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF). The report offers strategic insights and comprehensive analysis critical for biotech and pharmaceutical companies navigating the complexities of IPF clinical research and drug development.